ArticleAsian Pacific journal of cancer prevention : APJCP2025
nNav1.5 mRNA Expression in Triple Negative and Non-Triple Negative Breast Cancer Patients Treated at Hospital Pakar Universiti Sains Malaysia.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the expression of nNav1.5 mRNA and its association with clinicopathological features in triple-negative breast cancer (TNBC) and non-TNBC patients treated at Hospital Pakar Universiti Sains Malaysia (HPUSM), Kelantan.
methodsTumor tissue samples were collected from TNBC (n = 43) and non-TNBC (n = 19) patients. Real-time PCR was performed to measure nNav1.5 mRNA expression levels. Clinicopathological parameters assessed included tumor size, histological grade, cancer stage, hormone receptor status, HER2 expression, and lymph node involvement. Sanger sequencing was carried out to verify the identity of the amplified nNav1.5 transcripts.
resultsnNav1.5 mRNA expression was significantly higher in TNBC compared to non-TNBC tumors (p = 0.007). Sanger sequencing confirmed >99% sequence identity with the canonical human nNav1.5 transcript. Elevated nNav1.5 expression was significantly associated with TNBC subtype (p = 0.007), advanced tumor stage (p = 0.007), and distant lymph node metastasis (p = 0.002).
conclusionHigh expression of nNav1.5 mRNA in breast tumors is significantly associated with the TNBC subtype and aggressive clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.